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one agent were less likely to persist than those initiated on a prostaglandin analog. 
Those initiated on parasympathomimetic, beta blocking agent or on more than one 
agent were less likely to be compliant. Carbonic anhydrase inhibitors users were more 
likely to be compliant. CONCLUSIONS: Among the new antiglaucoma treatment 
users, 24% adhered to their treatment. The initial drug inﬂuences the likelihood of 
both persistence and compliance.
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OBJECTIVES: To assess French patient’s characteristics and ophthalmologists man-
agement of glaucoma in 2009. METHODS: An internet cross-sectional one-day 
 multicentre study led in France aimed at describing management of glaucoma (G)/
ocular hypertension (OHT)—deﬁned by an intraocular pressure q21 mm Hg, and also 
at assessing satisfaction and compliance. RESULTS: Two hundred eighty-eight oph-
thalmologists included 963 patients, 43.2% were male. Open-angle-glaucoma (OAG) 
in 71.7% and OHT in 24.3% of cases were motives for consultation. For OAG and 
OHT mean disease duration was respectively 9.2 o 7.7 years and 5.0 o 5.3 years. 
Mean age was respectively 58.2 o 12.9 and 54.7 o 12.5, mean IOP 17.5 o 4.9 and 
19.1 o 4.2 mm Hg. Average treatment duration was 8.0 o 7.1 years, mean number of 
treatment changes 2.0 o 2.3. Previous treatment consisted in laser in 16.2% of cases, 
surgery 10.5%, laser plus surgery 4.6%. Medical treatment was administered in 
94.0% of OAG patients and in 74.9% of OHT patients. Monotherapy was 50.7% 
of medical treatment, ﬁxed association 16.4%, non-ﬁxed associations 32.9%. In 
monotherapy group, beta-blockers (BB) part was 31.7%, prostaglandins (PG) 50.7% 
and carbonic anhydrase inhibitors CAI 5.9%. In ﬁxed association group BBPG were 
used in 72.5% of cases, BBCAI in 20.3% and BB ADR 6.5%. Whatever is the 
medical treatment, changes are secondary to lack of IOP control, visual ﬁeld or ocular 
imaging worsening, lack of tolerance, then weak compliance. Observed rates of very 
satisﬁed patients between BB group and PG are as follows: 37.2% CI95 [29.4; 45.8] 
vs. 28.9% CI95 [23.6; 34.9], rates of very compliant patients: 65.9% CI95 [57.4; 
73.5] vs. 61% IC95 [54.7; 66.9]. CONCLUSIONS: This study demonstrated the large 
part of medical treatment in OAG/OHT. Among them PG are mostly prescribed in 
monotherapy or ﬁxed association with a high level of satisfaction and compliance 
according physicians.
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OBJECTIVES: Psoriasis is a chronic skin disorder affecting 1,5–3% of population and 
its cost to the society has been estimated between $600 and $900/patient/year. Pre-
scription compliance, adherence to an appropriate follow-up program, and changes 
in patients everyday lives represent an essential approach to reach and maintain clini-
cal remission. Our study wants to measure psoriasis related self-efﬁcacy through a 
questionnaire speciﬁcally developed for this purpose (Psoriasis Empowerment Enquiry 
in the Routinely practice or PEER). METHODS: The study was an observational, 
cross-sectional survey. 240 consecutive psoriatic outpatients were asked to ﬁll the 
questionnaire. The PEER is a 20-item Likert-type questionnaire and generates an 
overall empowerment score obtained by summing individual items; since we have 
deﬁned empowerment as mastering the knowledge about psoriasis, learning from past 
experiences and owning skills to combine both to comply with recommendations of 
physicians, the PEER was conceived with 3 subscales. RESULTS: A total of 223 
respondents were analyzed. Psoriatic patients more than 44 years old reported higher 
values in the overall score (p  0.01) and in the skills subscale score (p  0.03) while 
educational level didn’t affect it. People suffering from psoriasis from more than one 
year had a higher overall (p  0.005) and knowledge subscale (p  0.001) scores but 
no signiﬁcant score differences were recorded comparing the number of consultations; 
psoriatic arthritis cases reported higher scores (p  0.001) than those affected by others 
psoriasis subtype. CONCLUSIONS: patients older than age 44, arthropathic patients 
or cases affected from more than one year reported higher scores reﬂecting a higher 
level of empowerment; psoriatic patients are in great need for self-management of their 
chronic disease. We introduce a questionnaire to survey empowerment among psoria-
tic patients that could represent a useful tool to evaluate the efﬁcacy of any kind of 
interventions in this disabling skin disorder.
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OBJECTIVES: This study was conducted to examine the face and content validity as 
well as psychometric properties of the Eyelash Satisfaction Questionnaire (ESQ) 
among cancer patients. Additionally, the aim was to determine whether the measure-
ment properties were equivalent across non-cancer and cancer patients. METHODS: 
Two focus groups (n  15) were conducted among cancer patients post-chemotherapy 
to examine the validity of the conceptual framework and test the face and content 
validity of the ESQ. A web survey was conducted among adults with cancer. Classical 
Test Theory (CTT) and latent variable modeling techniques were performed using data 
collected from the web survey. Conﬁrmatory Factor Analysis (CFA), Multiple Group 
Structural Equation Modeling (MG-SEM), and Differential Item Functioning (DIF) 
were performed to examine the accuracy and stability of the three domains between 
non-cancer (n  909) and post-chemotherapy cancer samples (n  595) in the US. 
RESULTS: Qualitative analysis of the focus group discussions indicated that the con-
ceptual framework established for cancer patients was similar to that for non-cancer 
patients. Additionally, support was found for the face and content validity of the ESQ. 
Internal consistency was found to be high across all three domains (Cronbach’s 
A  0.93, .90, 0.80) and item-to-domain correlations were high (.55–.84). The factor 
structure of the original survey ﬁt the cancer data well with factor loadings ranging 
from .64 to 93. Measurement invariance models provided good ﬁt to the data 
(NNFI  0.97, RMSEA  0.04). Signiﬁcant DIF was found between the two samples 
on two items but the effect sizes of the differences were small (Cohen’s d’s  0.10) 
and substantively negligible. CONCLUSIONS: The research ﬁndings indicate good 
overall performance of the ESQ among cancer patients providing support for its use 
in this population. Additionally, the measurement properties between non-cancer and 
cancer patients were found to be equivalent.
PSS33
DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-
RELATED QUALITY OF LIFE IN PATIENTES WITH PSOARIASIS: 
‘PSO-LIFE’
Sánchez-Carazo JL1, Daudén E2, Herrera E3, Toribio J4, Puig L5, Sabater FJ6, Perulero N7, 
Badia X7
1Hospital General de Valencia, Valencia, Spain, 2Hospital La Princesa, Madrid, Spain, 3Hospital 
Universitario Virgen de la Victoria, Málaga, Spain, 4C.H.U. Santiago (Hospital Gil Casares), 
Santiago de Compostela, Spain, 5Sant Pau, Barcelona, Spain, 6Schering-Plough S.A, 
Alcobendas, Spain, 7IMS Health, Barcelona, Spain
OBJECTIVES: It is important that a questionnaire can detect impact on HRQoL when 
the disease is ‘active’ and when is not active in patients with Psoriasis. We have 
developed a new questionnaire where the items have been created to evaluate the 
impact of the disease in different phases. METHODS: In order to deﬁne the main 
dimensions, a literature review and a F.G with 5 dermatologists were performed. A 
semi-structured interview was conducted with 20 patients (10 with active and 10 with 
non active). From the content of the interviews several items were identiﬁed. Each 
item was subsequently rated by the dermatologist. The items were administered to a 
sample of 171 patients (52.1% active and 47.9% non active). A factor analysis and 
a Rasch analysis were performed to obtain the ﬁnal pilot questionnaire before the 
validation study. RESULTS: After qualitative reduction, a 37 items questionnaire was 
obtained (score 0; poor HRQoL to 100; good HRQol) (PSO-LIFE 37). Factor analysis 
identiﬁed 6 dimensions (variance explained of 72.4%). Rasch analysis was used to 
exclude those items with INFIT or OUTFIT  1.30 and 0.70 or redundant with other 
items. This ﬁnal questionnaire (PSO-LIFE 20) has good internal consistency (Cron-
bach’s alpha  0.94). Comparative psychometric performance between PSO-LIFE 37 
and PSO-LIFE 20 showed similar internal consistency (0.97 and 0.94), and item cor-
relation-overall score (0.34–0.82 and 0.35–0.81). PSO-LIFE 20 showed differences 
(p  0.042) with severity of psoriasis and between patients with active and non active 
disease (p  0.01) (high score in patients with mild severity, and in patients with non 
active, which reﬂect good HRQoL). CONCLUSIONS: PSO-LIFE is a new question-
naire of 20 items, with a priori good psychometric properties though validation is 
needed through a formal validation process in a sample of adequate size. Preliminary 
results show that highest impact on HRQoL is observed in patients with active 
disease.
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BACKGROUND: The number of patients with atopic dermatitis is increasing., AD 
in industrialized countries concerns 5 to 20 % of children between 6&7 years old, of 
which nearly 10% still suffer from this disease during adulthood. Consequently; atopic 
dermatitis has become a true public health concern with namely difﬁculties in diag-
nosis and patient’s management. OBJECTIVES: In order to rapidly and effectively 
refer patients with AD to dermatologists or paediatricians, our work has aimed at 
designing and validating a questionnaire of presumed diagnosis of AD METHODS: 
This questionnaire was designed and based on a large review of international scientiﬁc 
literature, in particular from articles about diagnosis criteria by Haniﬁ and Rajka and 
the UK Working Party, interviews of experts and a series of structured interviews of 
patients with AD of different levels of severity, hence forming a rich and structured 
verbatim. RESULTS: A questionnaire, using simple vocabulary, and comprising 20 
questions, has been designed. Answers to each question are dichotomic; the subject 
answering either « yes » or « no », so as to prevent any confusion. During test phase, 
it was found necessary to add « do not know »as a possible answer. 8 questions focus 
on the medical history of the patient and his/her family (parents and brothers/sisters), 
2 questions dealt with difﬁculties in getting to sleep as well as the quality of sleep, 9 
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questions looked into the skin condition, and one question described the localization 
of possible lesions on the skin. Moreover, a psychometric validation has enable to 
conﬁrm the internal consistency and very good reproducibility of the questionnaire 
CONCLUSIONS: The ongoing validation study carried in several dermatology hos-
pital units will allow to determine 3 levels of presumed diagnosis of Atopic Dermatitis: 
«unlikely», «likely» or «possible»; which will help the caregiver decide whether the 
patient should be referred to a dermatologist to get appropriate treatment.
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OBJECTIVES: To develop a brief self-administered questionnaire able to measure 
patient satisfaction with treatments of skin diseases of the hands, with good psycho-
metric properties. METHODS: An initial version of the questionnaire composed by 
38 items, organized in 6 dimensions, was proposed. Items were extracted from 3 
patient’s focus-groups and ratiﬁed by a 7 expert panel and were presented to a pilot 
sample to test comprehension. This full version was administered to a sample of 217 
patients with skin diseases of the hands recruited at 18 representative hospitals in 
Spain. In order to assess convergent validity Morisky-Green compliance scale, SF-12 
HRQoL questionnaire and a health status VAS were also used. Treatment effectiveness 
and tolerability were also measured. Exploratory factor analysis was used for item 
reduction and conﬁrmatory factor analysis for dimensionality assessment. Internal 
consistency and split-half methods were used for reliability. Item discrimination and 
kwon group’s validity (gender, age, severity, and treatment) were also assessed. 
RESULTS: The reduction and validation sample was composed by 54% women, and 
a mean age of 43 years (sd  13.7). Questionnaire was reduced to 17 items arranged 
in 6 dimensions: Efﬁcacy, Ease of use, Impact on HRQoL, Follow up, Undesired 
Effects, General Opinions. Cronbach’s alpha attained a 0.9 value. Dimensions exhib-
ited levels of correlation different from those found previously from questionnaires 
for other pathologies. The overall score distributed normally with 58.4 mean 
(sd  18.01). Dimension scores correlated within 0.003 and 0.222 with HQoL measures, 
correlated higher with effectiveness (r  0.41) and tolerability (0.22), but very low 
with compliance (0.015). Signiﬁcant differences were found between some diagnoses 
and treatments. CONCLUSIONS: The reduced questionnaire presents good psycho-
metric properties, with an excellent reliability and good initial validity evidences.
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OBJECTIVES: Skin scars impact quality of life (QoL), quantiﬁcation of which is 
essential to evaluate the effectiveness of treatment. As no suitable instruments were 
available the objective of the study was to develop and validate the ﬁrst patient-reported 
scale of scar-speciﬁc symptoms and QoL. METHODS: Questionnaire content was 
derived from qualitative interviews with UK scar patients. Face and content validity 
were assessed by cognitive debrieﬁng interviews conducted with patients. The ﬁnal 
instrument was determined using Rasch analysis and psychometrically assessed in a 
validation survey. RESULTS: Five hundred and sixty-seven potential items were 
extracted from 34 qualitative interview transcripts. Following review and reduction, 
16 symptom and 36 QoL items were identiﬁed. The draft scales were found to be rel-
evant, clear and easy to use in 16 patient interviews. Two QoL items were deleted as 
patients considered them too extreme. Following the validation survey (n  103), 10 
QoL and 3 symptom items were removed: eight misﬁt the Rasch model (Chi2 p  
0.05); four were redundant and one functioned differently according to age. Rasch 
analysis conﬁrmed two unidimensional scales (p  0.05). Internal consistency was good    
for both the symptoms and QoL scales (0.84 and 0.85) as was test-retest reliability 
(0.83 and 0.89 respectively). The symptom scale was shown to be statistically signiﬁ-        
cantly related (as expected) to scores on the Hospital Anxiety and Depression Scale 
(HADS) and the clinician-completed Manchester Scar Score (MSS). The QoL scale 
was also statistically signiﬁcantly related to scores on these measures and on patient-
reported scar severity. CONCLUSIONS: PRISM is the ﬁrst scientiﬁcally rigorous 
patient-reported instrument designed speciﬁcally for scar patients. It consists of two 
unidimensional scales with good psychometric and scaling properties: QoL (24 items) 
and symptoms (13 items). PRISM is well accepted by patients, easy to use and should 
prove valuable for assessing scar disease severity in clinical trials and practice.
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OBJECTIVES: The Quality of Life (QoL) impact of chronic hand eczema (CHE) is 
expected to be signiﬁcant because of the high functional, social and psychological 
impact of this disease but has rarely been assessed with validated tools. This study 
determined the effect of CHE severity on patient QoL by the Dermatology Life Quality 
Index (DLQI). METHODS: Data from a Phase II study of oral alitretinoin for the 
treatment of moderate to severe CHE unresponsive to potent topical corticosteroids 
was used to measure changes in QoL according to Physician’s Global Assessment 
(PGA) of disease severity. 162 matched DLQI and PGA observations were analysed 
using mixed models. The PGA is a global 5-point rating of CHE severity based on 
multiple signs and symptoms. The DLQI is a simple questionnaire validated in several 
skin diseases and different languages. Ten questions scored 0–3 are summed, with a 
total score of 0 (best QoL) to 30 (worst QoL). DLQI  5 is considered clinically sig-
niﬁcant and DLQI 11–20 is considered to indicate a very large impact of skin disease 
on QoL. RESULTS: Increasing severity of CHE was associated with a conditional 
mean DLQI score as follows: ‘clear/almost clear’ 1.74, ‘mild’ 5.93, ‘moderate’ 9.78, 
and ‘severe’ 15.08. Changes in DLQI score from PGA ‘severe’ to milder states during 
the 12 week study were as follows: ‘moderate’ (5.30), ‘mild’ (9.15), ‘almost clear’ 
(12.03), and ‘clear’ (14.56). All changes were statistically signiﬁcant (p  0.0001) 
and exceeded the Minimal Important Difference (MID) for CHE estimated to be 2.53 
in a recent German observational study. CONCLUSIONS: The QoL of patients with 
CHE is signiﬁcantly inﬂuenced by clinical disease severity as measured by the PGA 
instrument. Treatment which reduces clinical severity of CHE is likely to be worth-
while from the patient perspective in view of the signiﬁcant improvement in QoL that 
may result.
PSS38
INFLUENCE OF DEPRESSION ON HEALTH RELATED QUALITY OF  
LIFE IN PSORIASIS: RESULTS FROM AN OPEN LABEL STUDY OF 
ADALIMUMAB IN PATIENTS WITH PSORIASIS
Qian H1, Guh D1, Papp K2, Goyette A3, Teixeira H4, Zhang W1, Bansback N5
1Centre for Health Evaluation and Outcomes Research, Vancouver, BC, Canada, 2K. Papp 
Clinical Research, Probity Medical Research, Waterloo, ON, Canada, 3Abbott, Saint-Laurent, 
QC, Canada, 4Abbott Canada, Saint-Laurent, QC, Canada, 5Centre for Health Evaluation 
and Outcome Sciences, Vancouver, BC, Canada
BACKGROUND: Recent studies have demonstrated the efﬁcacy of adalimumab on 
improving psoriasis symptoms, health related quality of life (HRQoL), and depression. 
OBJECTIVES: To quantify the importance of depression on overall HRQoL in 
patients with active plaque psoriasis who were enrolled in an open label clinical study 
of adalimumab. METHODS: PRIDE (A Canadian Open-Label Access PRogram to 
Evaluate the Safety and the Effectiveness of Adalimumab When Added to InaDEquate 
Therapy for the Treatment of Psoriasis) was an open-label, multicenter, Phase IIIb 
study in Canada. Patients with active moderate to severe plaque psoriasis who failed 
to respond to, or were intolerant of, standard prior therapies received adalimumab 
(80 mg) at Week 0 followed by adalimumab (40 mg) every other week. Changes in               
the outcomes including the Psoriasis Area and Severity Index (PASI), Beck Depression 
Inventory-II (BDI) and EQ-5D VAS at baseline, weeks 16 and 24 were evaluated. A 
multivariate mixed-effect regression was ﬁtted to identify the independent contribution 
of skin severity (PASI) and depression (BDI) on HRQoL (EQ-5D VAS). RESULTS: A 
total of 203 patients (61% male, mean age:46, mean PASI:20) were enrolled at 26 
sites. Statistically signiﬁcant improvements in PASI, EQ-5D VAS and BDI were seen 
at week 16 (improvements of 16.0, 10.1, 4.2, respectively all p  0.001) and 24 
(improvements of 16.1, 10.7, 4.3, respectively all p  0.001). The model found that 
both PASI (B  0.40, p  0.004) and BDI (B  0.54, p  0.002) were independent 
predictors of EQ-5D VAS. The interaction between BDI and females was also signiﬁ-
cant (B  0.64, p  0.006). CONCLUSIONS: HRQoL in patients with plaque psoria-
sis is inﬂuenced independently by both skin severity and depression. While the etiology 
of depression is likely through skin severity, it appears likely that both contribute to 
the improvements in HRQoL seen with adalimumab treatment.
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OBJECTIVES: There is limited data available on the economical burden of psoriasis 
and its impact on everyday life from the patient perspective. The aim of the study was 
to measure the burden of psoriasis for the patient. METHODS: We performed 
a cross-sectional study in French psoriasis patients. All patients aged q18 years 
with a diagnosis of plaque-psoriasis conﬁrmed by a physician were included. A self-
administered questionnaire evaluating everyday life was constructed with members of 
the French association of psoriasis patients. In addition the Dermatology Life Quality 
Index (DLQI), Working Productivity and Activity Impairment (WPAI) and individual 
costs were assessed. RESULTS: A total of 590 patients completed the survey. Mean 
age of the responders was 56 years. The mean DLQI score was 8.5 for patients with 
severe psoriasis versus 6.4 for mild psoriasis. Global loss of productivity was 10.7% 
without signiﬁcant difference according to the disease severity. Daily activities altera-
tion was most important in patients with severe psoriasis. A total of 36.8% of patients 
with severe psoriasis reported a negative impact on their professional life versus 19.6% 
for patients with mild psoriasis. Time devoted to phototherapy was on average 33 
hours/year/patient and the application of emollients took 25 hours/year/patient. 47.3% 
of patients had a feeling to clean the house more often, in correlation with the severity 
of the disease. Patients with severe psoriasis received more often aid from their family 
